Akero Therapeutics (AKRO) to Release Earnings on Friday

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) will likely be posting its Q4 2024 quarterly earnings results before the market opens on Friday, February 28th. Analysts expect Akero Therapeutics to post earnings of ($0.98) per share for the quarter.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). On average, analysts expect Akero Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Akero Therapeutics Stock Performance

AKRO traded up $1.37 on Friday, hitting $49.12. 648,276 shares of the company's stock were exchanged, compared to its average volume of 1,566,351. The stock has a fifty day moving average of $38.92 and a two-hundred day moving average of $32.57. The firm has a market cap of $3.43 billion, a PE ratio of -13.10 and a beta of -0.11. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics has a twelve month low of $17.86 and a twelve month high of $58.40.

Insider Buying and Selling

In other news, VP Patrick Lamy sold 5,000 shares of the business's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $57.03, for a total value of $285,150.00. Following the sale, the vice president now owns 33,492 shares in the company, valued at approximately $1,910,048.76. The trade was a 12.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Cheng sold 25,000 shares of the company's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $32.09, for a total transaction of $802,250.00. Following the sale, the chief executive officer now directly owns 605,417 shares in the company, valued at $19,427,831.53. This represents a 3.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 208,992 shares of company stock worth $9,633,413 in the last 90 days. 7.94% of the stock is owned by company insiders.

Remove Ads

Analysts Set New Price Targets

A number of research firms have recently weighed in on AKRO. UBS Group lifted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a report on Friday, January 31st. Morgan Stanley increased their price target on Akero Therapeutics from $46.00 to $96.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. HC Wainwright lifted their price objective on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a "buy" rating in a research note on Monday, January 27th. Citigroup increased their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Finally, Canaccord Genuity Group boosted their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $75.86.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.